Vaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference
September 21, 2023 08:00 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that senior management will participate in a fireside chat at the 2023 Cantor Global...
Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
September 06, 2023 16:05 ET
|
Vaxart, Inc.
Study met 5 of 6 primary endpoints Vaccine was safe and well tolerated with no vaccine-related serious adverse events (SAEs) Vaccination led to a statistically significant reduction in infection...
Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results
August 03, 2023 16:01 ET
|
Vaxart, Inc.
On track to report topline data from Phase 2 GI.1 norovirus vaccine challenge study in Q3 2023 Cash runway extended into Q3 2024 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.,...
Vaxart to Host Second Quarter 2023 Business Update and Financial Results Conference Call on August 3
July 27, 2023 08:00 ET
|
Vaxart, Inc.
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report...
Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate
July 06, 2023 08:00 ET
|
Vaxart, Inc.
Met all primary endpoints: Vaccine was well-tolerated with robust immunogenicity Continue to expect topline data from Phase 2 GI.1 challenge study in Q3 2023 SOUTH SAN FRANCISCO, Calif., July 06,...
Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement
June 26, 2023 16:45 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today held its Annual Meeting of Shareholders in a virtual-only format. Preliminary results from the Annual...
Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ET
June 21, 2023 16:30 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today encourages its stockholders of record on April 28, 2023, to vote on its proxy if they have not yet...
Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock
June 07, 2023 09:16 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the pricing of its underwritten public offering of 16,000,000 shares of its common stock,...
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
June 06, 2023 16:01 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has commenced an underwritten public offering of its common stock. In addition,...
Vaxart Announces Last Subject Dosed in Phase 2 Trial of its Bivalent Norovirus Candidate, and All Subjects Challenged in Phase 2 Challenge Study of Monovalent Norovirus Candidate
June 06, 2023 08:00 ET
|
Vaxart, Inc.
No Vaccine Related Serious Adverse Events (SAEs) reported to date On track to report topline data from two Phase 2 norovirus vaccine studies over the next 3 months SOUTH SAN FRANCISCO, Calif., June ...